Can NT-proBNP monitoring help prevent cardiovascular disease?

被引：0

作者：

Campbell, D. J. ^{[1
,2
]}

Woodward, M. ^{[3
]}

Chalmers, J. P. ^{[3
]}

Colman, S. A. ^{[3
]}

Jenkins, A. J. ^{[2
]}

Kemp, B. E. ^{[1
]}

Neal, B. C. ^{[3
]}

Patel, A. ^{[3
]}

MacMahon, S. W. ^{[3
]}

机构：

[1] Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic, Australia

[2] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic, Australia

[3] Univ Sydney, George Inst Int Hlth, Camperdown, NSW, Australia

来源：

RECENT ADVANCES IN CARDIOVASCULAR DISEASE: PROCEEDINGS OF THE 13TH WORLD CONGRESS HEART DISEASE | 2007年

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In subjects with cerebrovascular disease, plasma NT-proBNP levels assist the identification of increased risk for congestive heart failure, myocardial infarction, and ischemic stroke. Given that perindopril-based blood pressure-lowering therapy reduced the risk of these events, we investigated whether it also reduced NT-proBNP levels. Blood pressure reduction was similar for subjects with different baseline levels of NT-proBNP and was associated with reduced NT-proBNP levels in those subjects with elevated NT-proBNP (> 26 pmol/L), with a median reduction of 16 pmol/L (interquartile range 0-51 pmol/L, P=0.004), corresponding to a median decrease of 39% (interquartile range 0-69%). We conclude that plasma NT-proBNP level, in addition to predicting cardiovascular risk, may provide a measure of risk reduction by blood pressure-lowering therapy.

引用

页码：331 / +

页数：3

共 50 条

[1] NT-proBNP and Cardiovascular Dysfunction in Chronic Liver Disease
Cozma, Lucia Corina Dima
Ghiciuc, Cristina Mihaela
Mitu, Florin
Dascalu, Cristina Gena
[J]. REVISTA DE CHIMIE, 2018, 69 (02): : 525 - 528
[2] Utility of NT-proBNP as screening for cardiovascular disease in health checkup examination
Kitagawa, F.
Ishii, J.
Kuno, A.
Nakashima, A.
Naruse, H.
Matsui, S.
Ishikawa, T.
Tanaka, I.
Hishida, H.
Ozaki, Y.
[J]. CLINICAL CHEMISTRY, 2008, 54 (06) : A79 - A79
[3] NT-proBNP: An independent predictor of cardiovascular events
Bibbins-Domingo, K
Ali, S
Wu, AHB
Schiller, NB
Whooley, MA
[J]. CIRCULATION, 2006, 113 (08) : E333 - E333
[4] Cardiovascular Effects of Sulfonylureas in Dependence of NT-proBNP
Legenstein, Sabine
Resl, Michael
Huelsmann, Martin
Pacher, Richard
Prager, Rudolf
Luger, Anton
Clodi, Martin
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2012, 124 : 9 - 9
[5] Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio
Jensen, Juliana
Ma, Li-Ping
Fu, Michael L. X.
Svaninger, David
Lundberg, Per-Arne
Hammarsten, Ola
[J]. CLINICAL RESEARCH IN CARDIOLOGY, 2010, 99 (07) : 445 - 452
[6] Glycosylation of NT-proBNP molecules and NT-proBNP immunoassays.
Katrukha, A.
Semenov, A.
Seferian, K.
Postnikov, A.
Koshkina, E.
Krasnoselsky, M.
Mukharyamova, K.
Tolstaya, A.
Filatov, V.
[J]. CLINICAL CHEMISTRY, 2007, 53 (06) : A23 - A23
[7] Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio
Juliana Jensen
Li-Ping Ma
Michael L. X. Fu
David Svaninger
Per-Arne Lundberg
Ola Hammarsten
[J]. Clinical Research in Cardiology, 2010, 99 : 445 - 452
[8] The cardiovascular marker NT-proBNP reflects disease severity in patients with multiple myeloma
Cho, A.
Pavo, N.
Wurm, R.
Adlbrecht, C.
Krauth, M.
Agis, H.
Huelsmann, M.
[J]. WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S319 - S321
[9] NT-proBNP as a Potential Marker of Cardiovascular Damage in Children with Chronic Kidney Disease
Skrzypczyk, Piotr
Okarska-Napierala, Magdalena
Pietrzak, Radoslaw
Pawlik, Katarzyna
Wascinska, Katarzyna
Werner, Bozena
Panczyk-Tomaszewska, Malgorzata
[J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
[10] Chapter 9 Natriuretic peptides (BNP and NT-proBNP) and risk of cardiovascular disease
Christenson, Robert H.
Myer, Gary L.
Cooper, Gerald R.
[J]. ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2010, 44 (03): : 454 - 458

← 1 2 3 4 5 →